EP1543026A1 - Transcriptional activator gene for genes involved in cobalamin biosynthesis - Google Patents
Transcriptional activator gene for genes involved in cobalamin biosynthesisInfo
- Publication number
- EP1543026A1 EP1543026A1 EP03750606A EP03750606A EP1543026A1 EP 1543026 A1 EP1543026 A1 EP 1543026A1 EP 03750606 A EP03750606 A EP 03750606A EP 03750606 A EP03750606 A EP 03750606A EP 1543026 A1 EP1543026 A1 EP 1543026A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cobr
- dna
- vitamin
- polypeptide
- genes involved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/42—Cobalamins, i.e. vitamin B12, LLD factor
Definitions
- the present invention relates to a transc ⁇ ptional activator gene for genes involved in cobalamin biosynthesis More precisely, it relates to a process for amplifying the production of cobalamins and, more specifically, of coenzyme B 12 by means of recombinant DNA 5 techniques
- Vitamin B ⁇ is a member of molecules termed cobalamins and whose structure is pre sented, in particular, in W091/1 1518 It has been used as agent for treating pernicious anemia, nervous diseases, methylmalonic acidu ⁇ a, and so on, and feed additives for fowls and domestic animals The industrial production of vitamin B
- the vitamin B ⁇ 2 production process by P. denitrificans is characterized in that the fermentation is performed under aerobic condition from the first to the end contrary to the anaerobic fermentation or periodic fermentation from anaerobic to aerobic condition by
- glycine betaine (betaine) is an essential substance for overproduction of vitamin B !2 in P. denitrificans. Betaine is generally known as an osmoprotectant, but it was metabolized as N-source, C-source, and energy source in P. denitrificans as reported for the family Rhizobiaceae. Betaine is converted to dimethylglycine and methionine by transferring a methyl group to homocysteine by betaine homocysteine transmethylase.
- S-Adenosyl methionine synthesized from methionine is used as a methyl donor in the introduction of eight methyl groups to the corrinoid ring in vitamin B ]2 synthesis.
- dimethylglycine synthesized from betaine is converted to glycine via sarcosine possibly by dimethylglycine dehydrogenase and sarcosine oxidase.
- Glycine is used for synthesizing 5-aminolevurinic acid (ALA), which is a common precursor for heme and vitamin B 12 , with succinyl-CoA through C4-pathway (Shemin pathway).
- ALA 5-aminolevurinic acid
- betaine is considered as a possible precursor for vitamin B ] 2 synthesis.
- the present invention provides a gene designated cobR, which encodes a transcriptional activator, designated CobR for genes involved in vitamin B ] 2 biosynthesis in P. denitrificans and the use of the gene or polypeptide for improving vitamin B ⁇ production or for screening of genes involved in vitamin B] 2 synthesis.
- the present invention additionally provides the use of CobR as a transcriptional activator for genes involved in betaine metabolism.
- cobR was found to be an essential gene for betaine metabolism in P. denitrificans
- restriction sites of cobR suggested that cobR was not included in the fragments as disclosed in US 5,691,163. Therefore, the present invention has made it possible to improve produc- tion of vitamin B ] 2 by appropriate expression of cobR without reducing betaine metabolism
- the present invention is directed to DNA sequences comprising a DNA sequence which encodes CobR, which is a transcriptional activator for genes involved in vitamin B ⁇ 2 synthesis, as disclosed in the sequence listing, as well as their complementary strands, or those which include these sequences, DNA sequences which hybridize, preferably under standard conditions with such sequences or fragments thereof and DNA sequences, which because of the degeneration of the genetic code, do not hybridize under standard conditions with such sequences but which code for polypeptides having exactly the same amino acid sequence
- Protocols for identifying DNA sequences by means of hybridization are known to the person skilled in the art
- the hybridization may take place under stringent conditions, that is to say only hybrids in which the probe and target sequence, I e the polynucleotides treated with the probe, are at least 70% identical are formed
- the stringency of the hybridization including the washing steps, is influenced or determined by varying the buffer composition, the temperature and the salt concentration
- the hybridization reaction is preferably carried out under a relatively low stringency compared with the washing steps
- a 5x SSC buffer at a temperature of approx. 50-68°C, for example, can be employed for the hybridization reaction.
- Probes can also hybridize here with polynucleotides which are less than 70 % identical to the sequence of the probe.
- Such hybrids are less stable and are removed by washing under stringent conditions. This can be achieved, for example, by lowering the salt concentration to 2x SSC and subsequently 0.5x SSC at a temperature of approx. 50-68°C being established. It is optionally possible to lower the salt concentration to O. lx SSC.
- Polynucleotide fragments for example, at least 70% or at least 80% or at least 90% to 95% identical to the sequence of the probe employed can be isolated by increasing the hybridization temperature stepwise in steps of approx. 1-2°C.
- “Stringent conditions” in the context of this invention mean that hybridization in a buffer, for example, consisting of 5 x SSC, 0.1%(w/v) N-lauroylsarcosine, 0.02%(w/v) SDS, 1 % blocking reagent (Roche Diagnostics, Cat. No. 1096 176) at 50°C overnight and two times of washing with 2 x SSC, 0.1 %(w/v) SDS for 5 min at room temperature and following two times of washing with 0.1 x SSC, 0.1%(w/v) SDS for 15 min at 68°C in the washing step of hybridization.
- a buffer for example, consisting of 5 x SSC, 0.1%(w/v) N-lauroylsarcosine, 0.02%(w/v) SDS, 1 % blocking reagent (Roche Diagnostics, Cat. No. 1096 176) at 50°C overnight and two times of washing with 2 x SSC, 0.1 %(w/v) SDS for
- the present invention also includes DNA sequences which are at least 80% to 85%, preferably at least 86% to 90%, and particularly preferably more than 90% identical to the DNA sequence according to SEQ ID NO: l or a fragment thereof.
- the present invention is also directed to functional derivatives of the polypeptides of the present invention.
- Such functional derivatives are defined on the basis of the amino acid sequences of the present invention by addition, insertion, deletion and/or substitution of one or more amino acid residues of such sequences wherein such derivatives still have the activity of the transcriptional activator for genes involved in vitamin Bj 2 synthesis.
- Such functional derivatives can be made either by chemical peptide synthesis known in the art or by recombinant means on the basis of the DNA sequence as disclosed herein by methods known in the state of the art. Amino acid exchanges in proteins and peptides which do not generally alter the activity of such molecules are known in the state of the art.
- polypeptides according to the invention include a polypeptide according to SEQ ID NO:2, in particular those with the biological activity of the transcriptional activator CobR for genes involved in cobalamin biosynthesis, and also those which are at least 80% to 85%, preferably at least 86% to 90%, more preferably at least 91% to 95%, and particularly preferably more than 95% identical to the polypeptide according to SEQ ID NO: 2 and have the activity mentioned.
- promoters can be used; for example, the original promoter existing upstream of the cobR gene, promoters of antibiotic gene such as the kanamycin resistence gene of Tn5, the ampicillin resistence gene of pBR322, and of the ⁇ -galactosidase of E. coli (lac), the trp-, tac-, trc-promoter, promoters of lambda phage and any promoters which can be functional in the hosts consisting of microorganism including bacteria such as E. coli, P. denitrificans, P. putida, Agrobacterium tumefaciens, A. radiobacter, and Sinorhizo- bium meliloti, mammalian cells, and plant cells.
- SD Shine-Dalgarno
- AGGAGG AGGAGG, and so on, including natural and synthetic sequence operable in the host cell
- transcriptional terminator inverted repeat structure including any natural and synthetic sequences operable in the host cell
- Cloning vector is generally a plasmid or phage which contains a replication origin, regulatory elements, a cloning site including a multiple cloning site and selection markers such as antibiotic resistance genes including resistance genes for ampicillin, tetracycline, chloramphenicol, kanamycin, streptomycin, gentamicin, spectinomycin etc.
- Examples for a vector for the expression of the gene in E. coli are selected from any vectors usually used in E. coli, such as pBR322 or its derivatives including pUC18 and pBlue- scriptll, pACYCl77 and pACYC184 and their derivatives, and a vector derived from a broad host range plasmid such as RK2 and RSF1010.
- a preferred vector for the expression of the object gene in P. denitrificans, P. putida, A. tumefaciens, A. radiobacter, or S. meliloti is selected from any vectors which can replicate in these microorganisms, as w r ell as in a preferred cloning organism such as E. coli.
- the preferred vector is a broad host range vector such as a cosmid vector like pVKlOO and its derivatives and RSF1010 and its derivatives, and a vector containing a replication origin functional in P. denitrificans, P. putida, A. tumefaciens, A. radiobacter, or S. meliloti and another origin functional in E. coli.
- Copy number and stability of the vector should be carefully considered for stable and efficient expression of the cloned gene and also for efficient cultivation of the host cell carrying the cloned gene.
- DNA sequences containing transposable element such as Tn5 can also be used as a vector to introduce the object gene into the preferred host, especially on a chromosome.
- DNA sequences containing any DNAs isolated from the preferred host to- gether with the object gene are also useful to introduce the desired DNA sequence into the preferred host, especially on a chromosome.
- Such DNA sequences can be transferred to the preferred host by transformation, transduction, transconjugation or electroporation.
- bacteria such as E. coli, P. denitrificans, P. putida, A. tumefaciens, A. radiobacter, S. meliloti, and any Gram-negative bacteria which are capable of producing recombinant CobR. Mutants of said microorganism can also be used in the present invention.
- the DNA sequence encoding CobR of the present invention may be ligated into a suitable vector containing a regulatory region such as a promoter and a ribosomal binding site and a transcriptional terminator operable in the host cell described above by well-known methods in the art to produce an expression vector.
- a regulatory region such as a promoter and a ribosomal binding site and a transcriptional terminator operable in the host cell described above by well-known methods in the art to produce an expression vector.
- a host cell carrying an expression vector various DNA transfer methods including transformation, transduction, conjugal mating, and electroporation can be used.
- the method for constructing a transformed host cell may be selected from the methods well known in the field of molecular biology. Usual transformation system can be used for E. coli and Pseudomonas. Transduction system can also be used for E. coli. Conjugal mating system can be widely used in Gram-positive and Gram-negative bacteria including E. coli, P. putida, S. meliloti and P. denitrificans.
- the present invention relates to a process for screening of genes involved in vitamin B 12 synthesis by using the polypeptide according to SEQ ID NO: 2, in particular those with the transcriptional activator activity mentioned. Because a transcriptional activator activates transcription of a gene by interacting with DNA upstream the gene to be activated, a DNA fragment interacting with the transcriptional activator can be isolated from genomic DNA fragments using a polypeptide of transcriptional activator. It can be expected that genes involved in vitamin Bn synthesis not only cob genes already isolated and identified are isolated by using affinity of polypeptide according to SEQ ID NO: 2 or its C-terminal part including DNA binding domain.
- Strains and plasmids Pseudomonas denitrificans PF1-48 is derived from strain MB580 (US 3,018,225) and it w r as deposited at DSMZ under the accession number DSM 15208 under the Budapest Treaty.
- Strain CEEX6 is a mutant, which does not consume betaine nor produce vitamin B ⁇ 2 , derived from PF1-48, and it was deposited at DSMZ under the accession number DSM 15207.
- Plasmid pGUS02 which was used in Example 3-( l ), was constructed as follows.
- a promoter-less ⁇ -gluculonidase gene (gus) was prepared from pBHOl (CLONTECH Laboratories, Inc, CA) by PCR with the following primers; N-GUS: SEQ ID NO:3 (tagged with Sma I and Nde I sites) and C-GUS: SEQ ID NO:4 (tagged with Xho I and Sac I). Then, the Sma l-Sac I fragment of gus was introduced between the Sma I and Sac I sites in pBluescriptll KS " (Stratagene, La Jolla, CA).
- Plasmid pETcobR which was used in Example 3-(2), was constructed as follows. To make Nde I site at the initiation codon of cobR, PCR with primers COBRNde: SEQ ID NO: 7, and COBR135R: SEQ ID NO: 8 against pCRIIcobRB (pCRH::4.5 kb Ba Ul) was performed.
- the 0.1 kb Nde 1-Sph I fragment from the PCR product was cloned into pUC18 between Nde I and Sph I sites and a clone that had the correct sequence was selected.
- the 0.1 kb Nde l-Sph I fragment and a 1.1 kb Sph 1-EcoR I fragment from pCRIIcobRB were cloned simultaneously into pUC18 between Nde I and EcoR I sites.
- E. coli ⁇ D8767 or DH5 and P. denitrificans strains were carried out by tri-parental conjugation method as follows.
- E. coli DH5 carrying pRK2013 having tra genes were used as a helper for conjugal transfer.
- E. coli strains were cultivated in LB with appropriate antibiotics at 37°C, and P. denitrificans strains were cultivated in LB at 30°C overnight. The portion of £ coli cultures were transferred to LB without antibiotics at 1% of inoculation size and cultivated for 6 hours. Cultures of P. denitrificans, donor E. coli, and helper E.
- transconjugants of P. denitrificans were selected from the cells grown on the filter by plating on LB agar with 100 ⁇ g/ml of streptomycin and 200 ⁇ g/ml of neomycin or 2.5 ⁇ g/ml of tetracycline. Gus assay
- the frozen sample was thawed at 4°C and 0.64 ml of Z buffer (60 mM Na 2 HP0 4 , 40 mM NaH 2 P0 4 , 10 mM KC1, 50 mM 2-mercaptoethanol (2-ME), 1 mM MgS0 4 -7aq, (add 2-ME just before use)) and 0.16 ml of Lysozyme solution (2.5 mg/ml Z buffer) were added to it. After mixing by vortex for 1 sec, the sample was incubated at 37°C for 5 min. Then, it was mixed for 1 sec. after addition of 8 ⁇ l of 10% Triton X- 100 and was placed on ice.
- Z buffer 60 mM Na 2 HP0 4 , 40 mM NaH 2 P0 4 , 10 mM KC1, 50 mM 2-mercaptoethanol (2-ME), 1 mM MgS0 4 -7aq, (add 2-ME just before use)
- Lysozyme solution 2.5 mg/m
- PNPG p-nitrophenyl- ⁇ -glucuronide
- the media used for vitamin B 12 synthesis are #688 for seed culture and CCM- 1 for main production.
- One liter of #688 (pH 7.4 adjusted with 1 N NaOH) contains beat molasses (90g), (NH 4 ) 2 HP0 4 (3 g), (NH 4 ) 2 S0 4 ( 1.5 g), MgS0 4 -7H 2 0 ( 1.5 g), and ZnS0 4 -7H 2 0 (30 mg).
- CCM- 1 contains sucrose (40 g), betaine ( 15 g), yeast extract Amberex 695AG ( 1 g), citric acid (6 g), Na-glutamate ( 1 g), KH 2 P0 4 (2 g), (NH 4 ) 2 S0 4 (2 g), MgS0 4 -7H 2 0 (4 g), FeS0 4 -7H 2 0 (60 mg), ZnS0 4 -7H 2 0 (20 mg), CaCl 2 -2H 2 0 (0.5 g), MnS0 4 -4-5H 2 0 ( 10 mg), CuS0 4 -5H 2 0 (0.5 mg),
- the CCM-1X which was used as a betaine-less medium in Example 3, is different from CCM- 1 in content of betaine (0 g) and Na-glutamate (10 g).
- Example 1 Isolation of the cobR gene from P. denitrificans
- Chromosomal DNA prepared from P. denitrificans PFl-48 was partially digested with Sal I, and 15-35 kb fragments of the partial digests were isolated from preparative agarose gel electrophoresis (agarose: 0.7%); the gel piece containing the objective fragments was cut out and the fragments were electro-eluted into TAE buffer consisting of 40 mM Tris- acetate and 2 mM EDTA.
- 5 ⁇ g of the cosmid vector pVKlOO ATCC37156 was completely digested with Sal I and the digest was treated with a shrimp alkaline phos- phatase (United States Biochemical Corporation, Cleveland, USA) according to the supplier's recommendation.
- the dephosphorylated pVKlOO ( 130 ng) was ligated with the 15-35 kb fragments (33 ng) by the DNA ligation kit ver.l (Takara Shuzo, Co. Ltd., Kyoto, Japan) at 26°C for 10 min. Then, the ligate was used for packaging by phage coat protein using ⁇ in vitro packaging kit (Amersham Biosciences AB, Uppsala, Sweden) according to the supplier's protocol. The resulting phage particles were used for infection of f. coli ED8767, and about 400 kanamycin resistant colonies were obtained. These colonies were individually cultivated and the grown cells were stored at -80°C in 15% glycerol until use.
- CEEX6 When CEEX6 is cultivated in CCM-1 medium, the culture broth does not become auburn because of no production of vitamin B ]2 .
- genomic library was screened for gene that makes CEEX6 produce auburn pigment.
- About 400 cosmid clones described above were individually transferred into CEEX6 from E. coli ED8767 by conjugation and the resulting transconjugants were cultivated in the 100 ⁇ l of CCM- 1 in micro-titer plate with shaking at 30°C for 1 to 2 days.
- one clone CEEX6 carrying pS4F6 could make the medium auburn.
- the vitamin B 12 produc- tivity of the transconjugant in CCM- 1 was evaluated in shaking flask cultivation.
- CEEX6 carrying pS4F6 recovered vitamin B 12 production and betaine consumption simultaneous-
- Fig. 1 The localisation of the gene complementing CEEX6, i.e. cobR, in pS4F6 is shown in Fig. 1 where it is depicted with EcoR I sites. Subclones from pS4F6 are also shown with complementation ability of CEEX6 on pigment and vitamin B 12 production and betaine consumption. Each EcoR I fragment (E1-E6) does not complement CEEX6 in pigmentation ability (E7 was not tested).
- E EcoR I
- Et £coT22 I
- H Hind III
- P Pst l
- S Sal l
- X Xho ⁇ .
- each EcoR I fragment did not give CEEX6 pigmentation ability.
- one of deletion mutants with Sal I, pS4F6 ⁇ S94 which had about 7 kb insert and only one EcoR I site in it, could make C ⁇ X6 produce auburn pigment in the medium.
- pS4F6 ⁇ S39 which was different from pS4F6 ⁇ S94 in shortage of a 1 kb Sal I fragment, did not give the pigmentation ability to CEEX6. Then, further deletion mutants from pS4F6 ⁇ S94 were constructed and analyzed.
- Plasmid pS4F6 ⁇ S110 which had only the 1 kb Sal 1 fragment, did not show the pigmentation ability
- pS4F6 ⁇ S132 which had the 1 kb Sal I fragment with the adjacent 3.2 kb one, showed the pigmentation ability. Therefore, the gene complementing CEEX6 should exist across the two Sal I fragments. Then, a 6.5 kb £coT22 I fragment was cloned, which completely included these two Sal I fragments, from pS4F6 between two £c ⁇ T22 I sites in kanamycin resistance gene on pVKlOO (pVKcobREt).
- 4.5 kb BamH I, 2.3 kb Xho I, and 1.9 kb Pst I frag- ments were prepared including the Sal I site between the two Sal I fragments using BamH I, Xho I, or Pst I site in the 3.2 kb Sal I fragment.
- the 4.5 kb BamH I fragment was replaced with the 1.7 kb Bgl II fragment including cos site of pVKlOO to construct pVKcobRB.
- the Xho I and Pst I fragments were introduced respectively at Xho I site and between two £coT22 I sites in the kanamycin resistance gene on pVKlOO to construct pVKcobRX and pVKcobRP. These clones were introduced into CEEX6 and assayed for vitamin B ⁇ 2 productivity and betaine consumption activity. As shown in Table 1 , all of the clones except for the clone carrying pVKcobRX and pVKlOO recovered vitamin B ⁇ 2 production and betaine consumption of CEEX6.
- CobR could be a transcriptional activator belonging to AraC/XylS family because it had the helix-turn-helix motif found by Motifs progoram in GCG(Genetics Computer Group, University Research Park, WI, USA) conserved among the family near C-terminal; Hth_Arac_Family_l motif (K,R,Q) (L,IN,M,A) x2 (G,S,T,A,L,IN) ⁇ (F,Y,W,P,G,D, ⁇ ) x2 (L,I,V,M,S,A) x ⁇ 4,9 ⁇ (L,IN,M,F) x2 (L,IN,M,S,T,A) (G,S,T,A,C,I,L) x3 (G,A, ⁇ ,Q,R,F) (L,IN,M,FN) x ⁇ 4,5 ⁇ (L,F,Y) x3 (F,Y,I,V,A) ⁇ (F,
- CEEX6 has mutation in cobR.
- the cobR gene from CEEX6 was cloned and its nucleotide sequence determined as follows. A 2.1 kb fragment including the whole ORF of cobR was amplified from chromosome of strain PFl-48 by PCR, and it was used as a probe after labeling with DIG. Because we found that the 4.5 kb BamH I fragment also existed in CEEX6 by Southern blotting analysis, the fragment was cloned by using colony hybridization method with the probe described above.
- pCRII vector (Invitrogen Corporation, Carlsbad, CA) carrying the 6.5 kb EcoT22 I fragment was mutated with pGPS2.1 (CAT gene in the Tn). From the mutated sample, 8 kb £coT22 I fragments including Tn were excised and introduced into pVKlOO to trans- form E.coli D ⁇ 5 ⁇ . As a result, we obtained 128 Cm resistant transformants carrying various mutated fragments. Then, these plasmids were individually transferred into CEEX6 for testing complementation ability of pigmentation. Thirteen of 128 transconjugants showed no complementation ability.
- FIG. 2 shows random mutagenesis against 6.5 kb £coT22 I fragment: Tn insertion sites investigated were mapped on the 6.5 kb EcoT22 I fragment. The ORF of cobR was shown as open box. Complementation ability of each fragment with Tn on pVKlOO against CEEX6 were expressed as plus or minus in parenthesis with mapped Tn insertion site.
- B BamH I
- E EcoR I
- ⁇ t £c ⁇ T22 I
- H Hind III
- P Pst I
- S Sal I
- X Xho I.
- Plasmid pVKTn26 which had a Tn insertion at the center of cobR between Hz ' ⁇ d III and Sal I (Fig. 2) was used for null mutant construction.
- the 1.9 kb Pst I fragment with Tn (3.3 kb in total) from pVKTn26 was inserted at the Pst I site of a suicide vector pSUP202 ⁇ , which was constructed by filling in the cohesive end of £coR I site in pSUP202 to disrupt CAT gene on the plasmid.
- CobR gene product CobR could be a transcriptional activator belonging to AraC family. Because cobR deficient mutants could not consume betaine nor produce vitamin B ⁇ , we predicted that genes involved in betaine metabolism and vitamin B ]2 synthesis were activated by CobR. In addition, betaine may be an effector molecule for CobR.
- pGus02 a promoter probe vector, which was constructed using gus as a reporter gene, to estimate expression level of cob genes.
- cobEABCD operon As a fragment including promoter for cobEABCD operon, a 0.7 kb H d III fragment covering 0.7 kb Bgl ⁇ 1-Hind III fragment corresponding to 59th-792nd nucleotide in the sequence of cobEABCD genes resistered by Crouzet et al. in GenBank (Accession No.
- M59236) which has about 500 bp of 5'-noncoding region and about 200 bp of coding region of cobE, was inserted at Hz ⁇ d III site of pGus02.
- a 1.1 kb Xho I fragment which has about 0.9 kb of 5'-noncoding region and 0.2 kb of coding region of cobR, was used as a fragment probably including a cobR promoter.
- the 1.1 kb Xho I fragment was inserted between two Sal I sites of pGus02a, which was constructed by insertion of multiple cloning sites from pUC19 between Hind III and BamH I sites of pGus02.
- units of pcobE-gus and pcobR-gus were respectively excised as 2.6 kb and 3 kb Xho I fragments from the vector and introduced at Xho I site of pVKlOO in the reverse direction to kanamycin resistance gene on the plasmid to construct pVKpcobEgus and pVKpcobRgus, respectively.
- the constructed plasmids were introduced into PFl-48 and CEEX6, and resulting transconjugants were cultivated in CCM-1 (betaine including medium) and CCM- 1X (betaine-less but glutamate amplified from 1 to 10 g/1), in which B ⁇ 2 was not produced though cells grew well.
- CobR cell free extract
- £ coli cells cultivated in 2 x 10 ml of LB supplemented with ampicillin overnight were transferred to 2 x 200 ml of the same medium and cultiva- ted for 4 hours at 37°C with shaking at 180 rpm.
- Cells were harvested by centrifugation at 4,000 x g for 10 min and washed once with 50 mM Tris-HCl (pH 7.5), 5 mM MgCl 2 .
- the washed cells were resuspended in the same buffer at a concentration of 0.2 g of wet cell/ml. Then, CFE from the cell suspension was prepared by passing through French pressure cell twice at 1500 kg/cm 2 and removing cell debris by centrifugation at 3,000 x g for 10 min. On the other hand, we prepared a 290 bp ( 18 to 307 from the initiation codon) fragment upstream of cobE (cobEFlRl) by using PCR and labeled it at the 3'-end with D1G-11- ddUTP by terminal transferase included in DIG Gel Shift Kit (Roche Diagnostics, Basel, Switzerland). According to the protocol recommended by the supplier, the gel shift assay was performed with the labeled fragment and the CFE. One ng of labeled fragment was incubated with
- CFE including 1.2 mg of protein in 15 ⁇ l of 20 mM HEPES, pH 7.6, 1 mM EDTA, 10 mM (NH 4 ) 2 S0 4 , 1 mM DTT, 0.2%(w/v) Tween 20, 30 mM KC1, 50 ng/ ⁇ l Poly[d(I-C)] , 5 ng/ ⁇ l Poly L-lysine for 15 min at room temperature for binding reaction. After addition of 5 ⁇ l of 0.25 x 60% TBE buffer, 40% glycerol, 10 ⁇ l of the sample mixture was applied onto polyacrylamide gel electrophoresis (6% acrylamide in 0.25 x TBE, running buffer: 0.25 x TBE, constant voltage at 80 V for 2 hours).
- CFE of £ coli including CobR was applicable for gel shift assay. It means we could demonstrate that CobR directly bound to the regulatory region of the cobEABCD operon. Then, CFE of the wild P. denitrificans strain PFl-48 was applied for gel shift assay in comparison with CFEs of CEEX6 (cobR with a point mutation) and Tn26 (cofcP-null mutant) as negative controls. These strains were cultivated in 200 ml of LB for
- Example 4 Purification of a truncated CobR for preparation of anti-serum against CobR Although it was difficult to express cobR efficiently in £ coli as well as other transcriptional activators belonging to the AraC/XylS family even by using strong promoters such as tac or T7 in PET system, we found that deletion of N-terminal side at Hind III site
- solubilized proteins were recovered by centrifugation at 3,000 x g for 10 min. At last, 125 mg protein in 2.5 ml buffer B was obtained. Two mg of protein was applied for preparative SDS- PAGE ( 15% acrylamide). The major protein band of CobR ⁇ NHd was cut out from the gel, and the gel slice was provided to prepare rabbit anti-CobR antiserum.
- Transcriptional activators that belong to AraC/XylS family have two HTH motifs near C- terminal. Sequence conservation at the first HTH motif is low and the highly divergent each other whereas the second HTH motif does not have such variation. The conserved sequence at the second HTH motif is a determining factor in classification of transcrip- tional activator into AraC/XylS family.
- CobR has the motifs in the C-terminal so that CobR ⁇ NHd, which has C-terminal half of CobR, kept the DNA binding motifs.
- Example 6 Vitamin B 12 production by cofoR-amplif ⁇ ed PFl-48
- PFl-48 carrying pVKcobRB and PFl-48 carrying pVKlOO were cultivated in seed culture medium #688 for 2 days at 30°C.
- the portion ( 1 ml) of seed culture broth was inoculated into 30 ml of CCM- 1 medium in a 500 ml EMF.
- These main fermentations were performed at 30°C, 220 rpm on a rotary shaker for 4 days.
- 5 ml of feed medium consisting of 450 g of sucrose, 120 g of betaine, 3 g of MgS0 4 -7aq, and 0.105 g of 5,6-dimethylbenzimidazole/L were added and the cultivation was continued for further two days.
- quantity of vitamin B 12 produced was measured by HPLC. As a result, the former strain produced 6% higher amount of vitamin B 12 than the latter did.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03750606A EP1543026B1 (en) | 2002-09-27 | 2003-09-23 | Transcriptional activator gene for genes involved in cobalamin biosynthesis |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02021603 | 2002-09-27 | ||
EP02021603 | 2002-09-27 | ||
PCT/EP2003/010572 WO2004031227A1 (en) | 2002-09-27 | 2003-09-23 | Transcriptional activator gene for genes involved in cobalamin biosynthesis |
EP03750606A EP1543026B1 (en) | 2002-09-27 | 2003-09-23 | Transcriptional activator gene for genes involved in cobalamin biosynthesis |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1543026A1 true EP1543026A1 (en) | 2005-06-22 |
EP1543026B1 EP1543026B1 (en) | 2006-08-02 |
Family
ID=32049968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03750606A Expired - Lifetime EP1543026B1 (en) | 2002-09-27 | 2003-09-23 | Transcriptional activator gene for genes involved in cobalamin biosynthesis |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060024796A1 (en) |
EP (1) | EP1543026B1 (en) |
JP (1) | JP2006516385A (en) |
CN (1) | CN1681840A (en) |
AT (1) | ATE335001T1 (en) |
AU (1) | AU2003271044A1 (en) |
BR (1) | BR0314681A (en) |
DE (1) | DE60307294D1 (en) |
WO (1) | WO2004031227A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109321614A (en) * | 2018-10-22 | 2019-02-12 | 山东泓达生物科技有限公司 | It is a kind of to promote the composition and its application that vitamin B12 ferments |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1885847B1 (en) * | 2005-05-26 | 2011-07-06 | Cytos Biotechnology AG | Scalable fermentation process |
WO2012133119A1 (en) * | 2011-03-28 | 2012-10-04 | 長瀬産業株式会社 | Method for producing ferritin |
CN104342390B (en) * | 2014-10-10 | 2017-03-15 | 中国科学院天津工业生物技术研究所 | A kind of Sinorhizobium meliloti strain and combinations thereof and application |
CN109837320A (en) * | 2019-03-27 | 2019-06-04 | 山东泓达生物科技有限公司 | A method of it improving denitrified pseudomonas and produces vitamin B12 |
CN110950938B (en) * | 2019-12-23 | 2021-09-28 | 中国科学院天津工业生物技术研究所 | Bi-component regulation and control system and application thereof in preparing vitamin B12In (1) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2698879B1 (en) * | 1992-12-09 | 1995-01-13 | Rhone Poulenc Biochimie | capsules modified in the catabolism of betaine, preparation and uses, in particular for the production of metabolites or enzymes. |
WO1999067356A2 (en) * | 1998-06-25 | 1999-12-29 | Dsm N.V. | Propionibacterium vector |
-
2003
- 2003-09-23 BR BR0314681-2A patent/BR0314681A/en not_active Application Discontinuation
- 2003-09-23 WO PCT/EP2003/010572 patent/WO2004031227A1/en active IP Right Grant
- 2003-09-23 EP EP03750606A patent/EP1543026B1/en not_active Expired - Lifetime
- 2003-09-23 JP JP2004540680A patent/JP2006516385A/en not_active Withdrawn
- 2003-09-23 AU AU2003271044A patent/AU2003271044A1/en not_active Abandoned
- 2003-09-23 AT AT03750606T patent/ATE335001T1/en not_active IP Right Cessation
- 2003-09-23 CN CNA038221489A patent/CN1681840A/en active Pending
- 2003-09-23 DE DE60307294T patent/DE60307294D1/en not_active Expired - Lifetime
- 2003-09-23 US US10/528,674 patent/US20060024796A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2004031227A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109321614A (en) * | 2018-10-22 | 2019-02-12 | 山东泓达生物科技有限公司 | It is a kind of to promote the composition and its application that vitamin B12 ferments |
Also Published As
Publication number | Publication date |
---|---|
WO2004031227A1 (en) | 2004-04-15 |
BR0314681A (en) | 2005-08-02 |
CN1681840A (en) | 2005-10-12 |
EP1543026B1 (en) | 2006-08-02 |
US20060024796A1 (en) | 2006-02-02 |
JP2006516385A (en) | 2006-07-06 |
DE60307294D1 (en) | 2006-09-14 |
AU2003271044A1 (en) | 2004-04-23 |
ATE335001T1 (en) | 2006-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pérez-Redondo et al. | The claR gene of Streptomyces clavuligerus, encoding a LysR-type regulatory protein controlling clavulanic acid biosynthesis, is linked to the clavulanate-9-aldehyde reductase (car) gene | |
KR101558622B1 (en) | Increased production of a target product via stabilization of mrna | |
RU2504584C2 (en) | METHOD FOR OBTAINING PYRROLOQUINOLINE QUINONE (PQQ) USING BACTERIUM OF Methylobacterium OR Hyphomicrobium TYPE | |
KR101070110B1 (en) | Aldehyde dehydrogenase gene | |
AU2608801A (en) | Increased lysine production by gene amplification | |
JPH10229885A (en) | New alcohol/aldehyde dehydrogenase | |
KR100312456B1 (en) | Gene Derived from Pseudomonas fluorescens Which Promotes the Secretion of Foreign Protein in Microorganism | |
US11858967B2 (en) | Compositions and methods for enhanced production of enduracidin in a genetically engineered strain of streptomyces fungicidicus | |
Peter et al. | Isolation of the putP gene of Corynebacterium glutamicum and characterization of a low-affinity uptake system for compatible solutes | |
Thöny-Meyer et al. | The Bradyrhizobium japonicum aconitase gene (acnA) is important for free-living growth but not for an effective root nodule symbiosis | |
Mohorčič et al. | Expression of soluble versatile peroxidase of Bjerkandera adusta in Escherichia coli | |
EP1543026B1 (en) | Transcriptional activator gene for genes involved in cobalamin biosynthesis | |
CN109517811B (en) | beta-ketoacyl-ACP synthetase mutant | |
CN109097315B (en) | Genetically engineered bacterium for high-yield lipopeptide and construction method and application thereof | |
JP4293637B2 (en) | Biosynthetic method capable of producing cobalamin | |
JP5109460B2 (en) | Novel microorganism used for production of 3-amino-4-hydroxybenzaldehyde, method for producing 3-amino-4-hydroxybenzaldehyde using the microorganism, and polymer obtained by the 3-amino-4-hydroxybenzaldehyde | |
JP4586149B2 (en) | Promoter and activation method thereof | |
US20030228672A1 (en) | Sorbitol dehydrogenases of ketogulonigenium species, genes and methods of use thereof | |
AU3163699A (en) | Gluconobacter suboxydans sorbitol dehydrogenase, genes and methods of use thereof | |
WO2000008170A1 (en) | Gene participating in the production of homo-glutamic acid and utilization thereof | |
JPH08266291A (en) | Controllable expression system,adjustable protein,gene coding this,expression cassette,microorganism containing it,preparation of protein and preparation of microorganism and host stock | |
US5976836A (en) | Methods and compositions for enhancing erythromycin production | |
JPH0856673A (en) | Dna coding for uroporphyrinogen iii methyltransferase and production of vitamin b12 using the same | |
JP4251446B2 (en) | Gene encoding aldehyde dehydrogenase | |
KR100533116B1 (en) | A Heat-resistant dTDP-Glucose Synthase and Its Gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050225 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20060802 Ref country code: LI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060802 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060802 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060802 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060802 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060802 Ref country code: CH Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060802 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060802 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060802 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060802 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060802 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60307294 Country of ref document: DE Date of ref document: 20060914 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060925 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061102 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061102 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061102 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061103 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061113 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070102 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EN | Fr: translation not filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20070503 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061103 Ref country code: FR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070511 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20070923 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060802 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070203 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060923 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060802 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070923 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060802 Ref country code: FR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060802 |